202 related articles for article (PubMed ID: 29558877)
1. Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis.
Liang X; Famure O; Li Y; Kim SJ
Prog Transplant; 2018 Jun; 28(2):124-133. PubMed ID: 29558877
[TBL] [Abstract][Full Text] [Related]
2. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
Luan FL
Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
[TBL] [Abstract][Full Text] [Related]
4. Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis.
Katada Y; Nakagawa S; Nagao M; Umemura K; Itohara K; Nishikawa A; Hashi S; Katsube Y; Hira D; Ohsumi A; Nakajima D; Date H; Terada T
Transpl Infect Dis; 2023 Dec; 25(6):e14141. PubMed ID: 37639301
[TBL] [Abstract][Full Text] [Related]
5. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
Taber DJ; Ashcraft E; Baillie GM; Berkman S; Rogers J; Baliga PK; Rajagopalan PR; Lin A; Emovon O; Afzal F; Chavin KD
Transpl Infect Dis; 2004 Sep; 6(3):101-9. PubMed ID: 15569225
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
[TBL] [Abstract][Full Text] [Related]
10. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation.
Jorgenson MR; Wong C; Descourouez JL; Saddler CM; Smith JA; Mandelbrot DA
Transpl Infect Dis; 2021 Aug; 23(4):e13617. PubMed ID: 33866643
[TBL] [Abstract][Full Text] [Related]
11. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.
Brum S; Nolasco F; Sousa J; Ferreira A; Possante M; Pinto JR; Barroso E; Santos JR
Transplant Proc; 2008 Apr; 40(3):752-4. PubMed ID: 18455007
[TBL] [Abstract][Full Text] [Related]
12. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.
Monforte V; Lopez C; Santos F; Zurbano F; de la Torre M; Sole A; Gavalda J; Ussetti P; Lama R; Cifrian J; Borro JM; Pastor A; Len O; Bravo C; Roman A
Am J Transplant; 2009 May; 9(5):1134-41. PubMed ID: 19344437
[TBL] [Abstract][Full Text] [Related]
13. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
[TBL] [Abstract][Full Text] [Related]
14. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
15. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS
Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
[TBL] [Abstract][Full Text] [Related]
18. The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis.
Räihä J; Ortiz F; Mannonen L; Loginov R; Lempinen M; Lautenschlager I; Helanterä I
Transpl Infect Dis; 2021 Aug; 23(4):e13577. PubMed ID: 33527660
[TBL] [Abstract][Full Text] [Related]
19. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
[TBL] [Abstract][Full Text] [Related]
20. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
